#### **CDER SBIA Webinar Series**



# Electronic Submission requirements for ANDAs: Are you ready?

#### **Jonathan Resnick**

Project Management Officer
Division of Data Management Services &
Solutions
Office of Business Informatics
Center for Drug Evaluation and Research
U.S. Food and Drug Administration

#### Julia Lee, Pharm.D.

Acting Deputy Director
Division of Filing Review
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research
U.S. Food and Drug Administration

November 21, 2016



## Agenda

- eCTD Requirements and Timeline
- Where to find eCTD resources
- The ESG (Electronic Submission Gateway)
- CDER eCTD Processing
- Common eCTD Deficiencies
- How OGD (Office of Generic Drugs) will handle eCTD deficiencies
- Questions

www.fda.gov



How would you characterize your ability to submit your ANDA in proper eCTD format?			
I'm an experienced expert		0%	(0)
○ I'm pretty good at it		0%	(0)
O Someone else in my company handles the eCTD		0%	(0)
I'm a beginner - that is why I am here.		0%	(0)
○ Wait. What is eCTD?		0%	(0)
No Vote			
	✓ Broadcast Results		



- May 5, 2017: NDA, BLA, ANDA and DMFs must be in eCTD format
- May 5, 2018: Commercial INDs must be in eCTD format
- Do not send Paper and/or non-eCTD submissions after these deadlines!



## eCTD Requirements and Timeline STUDY Data Standards Resources

#### What's New

- Studies that start after December 17, 2016 must be in standardized format for NDA, BLA and ANDA submissions
- Study Data Technical Conformance Guide
   <a href="http://www.fda.gov/ForIndustry/DataStandards/StudyDataStandards/default.htm">http://www.fda.gov/ForIndustry/DataStandards/StudyDataStandards/default.htm</a>

#### Validation Codes

See Technical Rejection for Study Data. Currently posted on eCTD Website at <a href="https://www.fda.gov/ectd">www.fda.gov/ectd</a>

#### When

CDER will start using the new validation criteria - TBD



- Submissions that do not adhere to the requirements stated in the binding eCTD Guidance will be <u>not be</u> <u>filed or received</u>
- Please see the eCTD web page <u>www.fda.gov/ectd</u> for further information





See the Guidance for a \*complete\* list of the "musts"

- Must submit electronic submissions using the eCTD version currently supported by FDA.
  - The version of eCTD currently supported is specified in the <u>Data Standards Catalog</u>
- Must obtain a pre-assigned application number by contacting the appropriate Center. How? Go to www.fda.gov/ectd

Find it in the eCTD
Submissions
Standards
catalog

Must follow the FDA eCTD technical specification
 Table of Contents Headings and Hierarchy.





Find these specifications and more in the <u>eCTD</u> <u>Submissions</u> <u>Standards</u> catalog

Must adhere to the formats and versions specified in the FDA Specifications for File Format Types Using eCTD Specifications.

- Must adhere to the FDA Portable Document Format (PDF) Specifications.
- Must use the eCTD replace operation rather than submitting the file as new if a document replaces a document previously submitted ...






- Must include FDA fillable 356h form for ANDA, NDA, BLA and electronic signature to enable automated processing of the submission ... Scanned images of FDA forms will not be accepted.
- Must Not submit paper copies of the application, including review & desk copies when submitting in eCTD format.



- Must use the FDA Electronic Submission Gateway for submissions 10 GB or smaller.
  - ✓ Submissions larger than 10GB may come via the Gateway or USB drive






#### Where to find eCTD resources

#### eCTD website - www.fda.gov/ectd

#### Electronic Common Technical Document (eCTD)



Links to eCTD

other resources

Specifications and

- Technical Rejection Criteria for Study Data (PDF added 11/7/2016)
- Update to eCTD Technical Conformance Guide (PDF added 10/19/2016)
- Update to PDF Specifications (PDF added 10/3/2016)
- Third Acknowledgement for Successful eCTD Submissions beginning 5/31/201
- Transmission Specification version 1.6 (added 3/4/2016)

#### eCTD Documentation and Resources

For a listing of Specifications, Supportive Files, M1 versions 1.3 and 2.3 documents related to eCTD, please refer to eCTD Submission Standards (XLS - 57KB) or eCTD Submission Standards (PDF - 91KB).

#### What are the eCTD **Specifications?**


ICH eCTD Specs 3.2.2 FDA eCTD - Module 1 eCTD CTOC Validation, File Format, **PDF** Supportive files & more



#### Where to find eCTD resources

#### **Getting Started Section**

eCTD website - www.fda.gov/ectd



- Electronic Submission Gateway (ESG)
  - Step by step instructions on obtaining an ESG account
- Submit a Sample eCTD or Standardized Data Sample
  - We offer a process to validate sample eCTD submissions and standardized study datasets
- Instructions on how to request a CDER or CBER Preassigned Application Number
- Study Data Standards Resources




#### Where to find eCTD resources

#### Other sections are available too...

- Guidances
- Presentations
- Additional Resources
- Technical Assistance

eCTD website - www.fda.gov/ectd





### Electronic Submission Gateway (ESG)

- If you are not currently an ESG submitter, <u>set up an account</u> <u>now</u>; process can take several weeks
- Most submitters use the "WebTrader Hosted Solution"
- There is no cost for an ESG account, but you must obtain a
   Digital Certificate for each person in your organization who will
   be sending files thru the ESG
- Submissions 10 GB or less must use the ESG starting May 5, 2017.
- Submissions over 10 GB may use the ESG or be submitted via physical media
- See the ESG website for complete instructions: <a href="http://www.fda.gov/esg">http://www.fda.gov/esg</a>

### CDER eCTD Processing



## Common reasons for rejections which prevent submission from processing to review division:

- Duplicate Submissions
  - You send the same submission sequence more than once
- Submitted to Wrong Center
  - Selecting wrong center when using gateway (e.g., CDER instead of CBER)
- Mismatched Application/Sequence Type
  - Specifying NDA in us-regional.xml while indicating ANDA in 356h Form
- Invalid File Type
  - Submitting file types such as .zip and .exe
- Not in Standard eCTD Format
  - Missing key files such as us-regional.xml and index.xml



Julia Lee, Pharm.D.

Acting Deputy Director
Division of Filing Review
Office of Regulatory Operations
Office of Generic Drugs



#### **Legibility and Font Size**

#### **BAD**

Font type	Font name
Sans Senf	Arial
	Arial Balic
	Artid Bold
	Arnal Bold Bulu
Non Proportional	Courier New
	Conriet New Bulls
	Course New Bold
	Courser New Bold Italic
Section	Times New Rotton
	Times New Roman Italia
	Times New Roman Bold
	Times New Roman Bold Balic
Other	Symbol
	Zapf Dinghats




### **Legibility and Font Size**

Font type	Font name
Sans Serif	Arial
GOOD	Arial Italic
	Arial Bold
	Arial Bold Italic
Non Proportional	Courier New
	Courier New Italic
	Courier New Bold
	Courier New Bold Italic
Serif	Times New Roman
	Times New Roman Italic
	Times New Roman Bold
	Times New Roman Bold Italic
Other	Symbol
	Zapf Dingbats





### **Legibility and Font Size**





#### **Legibility and Font Size**





Any documents provided in the ANDA submission should be in the correct orientation

#### Orientation








#### **Orientation**

Any documents provided in the ANDA submission should be in the correct orientation






#### **Hypertext Table of Contents and Bookmarks**


- Should be the same
- For documents 5 pages or longer
- Up to 4 levels deep in hierarchy
- Each item listed in the table of contents, which should include all tables, figures, publications, other references, and appendices that are essential for navigation
- Set magnification to Inherit Zoom



#### **Bookmarks**



## Really Bad




Bad



#### **Bookmarks**


#### **BAD**





#### **Bookmarks**

INTRODUCTION.....



TA	<b>\B</b> ]	LE	OF	CO	NTE	NTS


II.	BACKGROUND
III.	GENERAL POLICY
A.	Form FDA 356h (356h)
В.	Organization/Format
C.	Non-Payment of GDUFA Obligations
D.	Lack of a Designated U.S. Agent for a Foreign Applicant
E.	Failure to Provide Environmental Assessment or Claim of Categorical Exclusion
F.	Citing a Pending Suitability Petition as a Basis of Submission
IV.	REVIEWS FOR API
Α.	Starting Material
В.	Sterility Assurance Data
V.	CHEMISTRY, MANUFACTURING, AND CONTROL DEFICIENCIES
Α.	Inactive Ingredients
В.	Inadequate Stability1
C.	Packaging Amount Considerations

Bookmarks DO NOT match TOC



#### **Bookmarks**

#### GOOD



#### TABLE OF CONTENTS


II (IKO)
BACKGROUND
GENERAL POLICY
Form FDA 356h (356h)
Organization/Format
Non-Payment of GDUFA Obligations
Lack of a Designated U.S. Agent for a Foreign Applicant
Failure to Provide Environmental Assessment or Claim of Categorical Exclusion
Citing a Pending Suitability Petition as a Basis of Submission
REVIEWS FOR API
Starting Material
Sterility Assurance Data
CHEMISTRY, MANUFACTURING, AND CONTROL DEFICIENCIES
Inactive Ingredients

**Bookmarks match TOC** 

## Common eCTD Deficiencies **Bookmarks**

DUDDOCE





#### Table of Contents


1 CKI OBE
VERSION
SECURITY
FONTS GOOD
PAGE ORIENTATION
PAGE SIZE AND MARGINS.
SOURCE OF ELECTRONIC DOCUMENTS
METHODS FOR CREATING PDF DOCUMENTS AND IMAGES
IMAGE COMPRESSION TO REDUCE FILE SIZE
OPTIMIZE FOR FAST WEB VIEW
IMAGE COLOR MATCHING
USE OF THUMBNAILS
DOCUMENT NAVIGATION
INITIAL VIEW SETTINGS



#### **Leaf Titles**




#### GOOD



## FDA

#### Common eCTD Deficiencies

#### **STF** .xml Study Information



	1.2 A Single Exposure Study to Evalua
<u> </u>	Synopsis
⊕€	Study Report Body
⊕€	Protocol or Amendment Sample Case Report Form
	campic case riopoit roini
	IEC IRB Consent Form List
	List Description Investigator Site
_	Signatures Investigators
	List Patients With Batches
	Randomisation Scheme
	Audit Certificates Report
_	Statistical Methods Interim Analysis Plan
	Inter Laboratory Standardisation Methods Quality Assura
	Publications Based on Study
	Publications Referenced in Report
_	Discontinued Patients
	Protocol Deviations
	Patients Excluded from Efficacy Analysis
	Demographic Data
	Compliance and Drug Concentration Data
_	Individual Efficacy Response Data
	Adverse Event Listings
	Listing Individual Laboratory Measurements by Patient



#### How OGD will handle eCTD deficiencies



#### **Current Practice**

Separate set of 'eCTD Deficiencies'

Inadequately addressed →

LOSE GDUFA
GOAL DATE

### May 5, 2017

eCTD deficiencies will be counted as a minor deficiency

Inadequately addressed →

Refuse to Receive (RTR)



## Summary

- All documents submitted to the Agency, including contracted documents, must follow the standards set forth in the binding eCTD guidance
- Currently if deficiencies are not corrected within
   7 calendar days, you lose your goal date
- Beginning May 5, 2017 → RTR

#### Resources



- ANDA Filing Checklist
- ANDA Submissions -- Content and Format of Abbreviated New Drug Applications
- ANDA Submissions -- Refuse-to-Receive Standards
- <u>Electronic Common Technical Document (eCTD)</u>
- Providing Regulatory Submissions in Electronic Format -- Certain Human
   Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications
- Comprehensive Table of Contents Headings and Hierarchy
- eCTD Submission Standards
- Submitting High Quality eCTD Submissions to FDA/OGD (Presentation 09/11/13)
- eCTD Web Page
- ESG Web Page

### **Information For Industry**



#### Click for:

- Providing Regulatory Submissions in Electronic Format
- <u>Electronic Common Technical Document</u>
- eCTD Submission Standards
- ANDA Submissions RTR Standards
- PDF of today's slides
- eCTD questions should be sent directly to CDER ESUB at:



#### ESUB@fda.hhs.gov

Open Q&A begins shortly – type in your questions now.

Click Here for Evaluation and Certificate

Learn about other resources from CDER Small Business & Industry Assistance:

Visit Our Website!